Effects of a highly concentrated hypertonic saline-dextran volume expander on cardiopulmonary function in anesthetized normovolemic horses.
Conventional fluid resuscitation is unsatisfactory in a small percentage of equine emergency surgical cases because the large volumes of fluids required cannot be given rapidly enough to adequately stabilize the horse. In anesthetized horses, the volume expansion and cardiopulmonary effects of a small volume of highly concentrated hypertonic saline-dextran solution were evaluated as an alternative initial fluid choice. Seven halothane-anesthetized, laterally recumbent, spontaneously ventilating, normovolemic horses were treated with a 25% NaCl-24% dextran 70 solution (HSD) at a dosage of 1.0 ml/kg of body weight, IV, infused over 10 minutes, and the effects were measured for 120 minutes after infusion. Plasma volume expansion was rapid and significant (from 36.6 +/- 4.6 ml/kg to 44.9 +/- 4.8 ml/kg), and remained significantly expanded for the duration of the experiment. Packed cell volume, total blood hemoglobin, and plasma protein concentrations significantly decreased, confirming rapid and sustained volume expansion with hemodilution. Cardiac index and stroke index immediately increased and remained high for the entire study (from 69.6 +/- 15.3 ml/min/kg to 106.6 +/- 28.4 ml/min/kg, and from 1.88 +/- 0.49 ml/beat/kg to 2.50 +/- 0.72 ml/beat/kg, respectively). Systemic vascular resistance significantly decreased immediately after HSD infusion and remained decreased for the duration of the study (from 1.41 +/- 0.45 mm of Hg/ml/min/kg to 0.88 +/- 0.22 mm of Hg/ml/min/kg). Arterial and venous blood oxygen content decreased significantly because of hemodilution, but actual oxygen transport transiently increased at the 10-minute measurement before returning toward baseline.(ABSTRACT TRUNCATED AT 250 WORDS)
Moon
P F
PF
Veterinary Medical Teaching Hospital, Davis, CA 95616.
Snyder
J R
JR
Haskins
S C
SC
Perron
P R
PR
Kramer
G C
GC
D000136:Acid-Base Equilibrium; D000818:Animals; D001798:Blood Proteins / Q000032:analysis; D002302:Cardiac Output; D002496:Central Venous Pressure; D003911:Dextrans / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006339:Heart Rate; D006400:Hematocrit / Q000662:veterinary; D006439:Hemodynamics; D006454:Hemoglobins / Q000032:analysis; D006736:Horses / Q000502:physiology*; D006863:Hydrogen-Ion Concentration; D007773:Lactates / Q000097:blood; D008297:Male; D009994:Osmolar Concentration; D010100:Oxygen / Q000097:blood; D010952:Plasma Substitutes / Q000008:administration & dosage / Q000494:pharmacology*; D010953:Plasma Volume; D011188:Potassium / Q000097:blood; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage / Q000494:pharmacology*; D012964:Sodium / Q000097:blood; D013318:Stroke Volume; D014655:Vascular Resistance
D001798:Blood Proteins; D003911:Dextrans; D006454:Hemoglobins; D007773:Lactates; D010952:Plasma Substitutes; D012462:Saline Solution, Hypertonic; D012964:Sodium; D011188:Potassium; D010100:Oxygen